BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 25519251)

  • 1. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays.
    Douxfils J; Lessire S; Dincq AS; Hjemdahl P; Rönquist-Nii Y; Pohanka A; Gourdin M; Chatelain B; Dogné JM; Mullier F
    Thromb Haemost; 2015 Apr; 113(4):862-9. PubMed ID: 25519251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate.
    Douxfils J; Dogné JM; Mullier F; Chatelain B; Rönquist-Nii Y; Malmström RE; Hjemdahl P
    Thromb Haemost; 2013 Sep; 110(3):543-9. PubMed ID: 23783171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
    Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
    Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples.
    Helin TA; Lemponen M; Hjemdahl P; Rönquist-Nii Y; Lassila R; Joutsi-Korhonen L
    Thromb Res; 2015 Jul; 136(1):154-60. PubMed ID: 25981140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation.
    Skeppholm M; Hjemdahl P; Antovic JP; Muhrbeck J; Eintrei J; Rönquist-Nii Y; Pohanka A; Beck O; Malmström RE
    Thromb Res; 2014 Oct; 134(4):783-9. PubMed ID: 25172669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis.
    Schmohl M; Gansser D; Moschetti V; Stangier J
    Thromb Res; 2015 Mar; 135(3):532-6. PubMed ID: 25600440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma.
    Antovic JP; Skeppholm M; Eintrei J; Boija EE; Söderblom L; Norberg EM; Onelöv L; Rönquist-Nii Y; Pohanka A; Beck O; Hjemdahl P; Malmström RE
    Eur J Clin Pharmacol; 2013 Nov; 69(11):1875-81. PubMed ID: 23784008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
    Hapgood G; Butler J; Malan E; Chunilal S; Tran H
    Thromb Haemost; 2013 Aug; 110(2):308-15. PubMed ID: 23783268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of dabigatran in plasma, serum, and urine samples: comparison of six methods.
    Du S; Weiss C; Christina G; Krämer S; Wehling M; Krämer R; Harenberg J
    Clin Chem Lab Med; 2015 Jul; 53(8):1237-47. PubMed ID: 25720084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diluted thrombin time reliably measures low to intermediate plasma dabigatran concentrations.
    Božič-Mijovski M; Malmström RE; Malovrh P; Antovic JP; Vene N; Šinigoj P; Mavri A
    Ann Clin Biochem; 2016 Jul; 53(Pt 4):446-51. PubMed ID: 26392631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the ecarin chromogenic assay and diluted thrombin time for quantification of dabigatran concentrations.
    Jaffer IH; Chan N; Roberts R; Fredenburgh JC; Eikelboom JW; Weitz JI
    J Thromb Haemost; 2017 Dec; 15(12):2377-2387. PubMed ID: 28976630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparisons between diluted thrombin time, ecarin chromogenic assays, and UPLC-MS for plasma level dabigatran quantification: Results from DRIVING study.
    de Fautereau-Vassel A; Mokhtarian A; Mangenot M; Krekounian O; Kousignian I; Delavenne X; Curis E; Gouin-Thibault I; Siguret V
    Int J Lab Hematol; 2024 Feb; 46(1):120-127. PubMed ID: 37710085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The assessment of anticoagulant activity to predict bleeding outcome in atrial fibrillation patients receiving dabigatran etexilate.
    Chang YT; Hu YF; Liao JN; Chern CM; Lin YJ; Chang SL; Wu CH; Sung SH; Wang KL; Lu TM; Chao TF; Lo LW; Hsu LC; Chung CP; Chang PM; Hsu WH; Chiou CW; Chen SA
    Blood Coagul Fibrinolysis; 2016 Jun; 27(4):389-95. PubMed ID: 26991859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of dabigatran on thrombin generation and coagulation assays in rabbit and human plasma.
    Zhang C; Zhang P; Li H; Han L; Zhang L; Zhang L; Yang X
    Thromb Res; 2018 May; 165():38-43. PubMed ID: 29558660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Monitoring of Oral Thrombin Inhibitor].
    Matsuno K; Usami T; Hatuse M; Shimizu C
    Rinsho Byori; 2014 Oct; 62(10):958-64. PubMed ID: 27526541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basic coagulation tests as surrogates of dabigatran levels in a pre-operative setting: Analysis of five activated partial thromboplastin time reagents and thrombin time.
    Dubé C; Douketis JD; Moffat KA; Schulman S; Blais N
    Thromb Res; 2018 Nov; 171():62-67. PubMed ID: 30261356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabigatran Monitoring Was Influenced by Thrombin Time Reagent With Different Thrombin Concentrations.
    Xu X; Liang Q
    Clin Appl Thromb Hemost; 2019; 25():1076029619867137. PubMed ID: 31364394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism.
    Halton JML; Picard AC; Harper R; Huang F; Brueckmann M; Gropper S; Maas H; Tartakovsky I; Nurmeev I; Mitchell LG; Brandão LR; Chalmers E; Albisetti M
    Thromb Haemost; 2017 Nov; 117(11):2168-2175. PubMed ID: 29202215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples.
    Lind SE; Boyle ME; Fisher S; Ishimoto J; Trujillo TC; Kiser TH
    Am J Clin Pathol; 2014 May; 141(5):665-74. PubMed ID: 24713737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation.
    Okubo K; Kuwahara T; Takagi K; Takigawa M; Nakajima J; Watari Y; Nakashima E; Yamao K; Fujino T; Tsutsui H; Takahashi A
    Am J Cardiol; 2015 Jun; 115(12):1696-9. PubMed ID: 25918026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.